News
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
17 Apr 24
Analyst Ratings
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Guggenheim Downgrades Travere Therapeutics to Neutral
27 Mar 24
News, Downgrades, Analyst Ratings
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
13 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Maintains $17 Price Target
13 Mar 24
News, Price Target, Analyst Ratings
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
16 Feb 24
Analyst Ratings
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
16 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Earnings Scheduled For February 15, 2024
15 Feb 24
Earnings
Earnings Preview For Travere Therapeutics
14 Feb 24
Earnings
Travere Therapeutics Announces Licensing Agreement With Renalys Pharma To Develop And Commercialize Sparsentan In Japan, South Korea, Taiwan, And Southeast Asian Nations
25 Jan 24
Biotech, News, General
Press releases
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
4 Apr 24
News, Press Releases
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
3 Apr 24
News, Press Releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Mar 24
Press Releases, General
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11 Mar 24
Health Care, Press Releases
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Press Releases
Travere Therapeutics to Present at Upcoming Investor Conferences
26 Feb 24
News, Press Releases
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
23 Feb 24
Health Care, Press Releases
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
23 Feb 24
Press Releases
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 24
Earnings, Press Releases
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
8 Feb 24
Press Releases
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
1 Feb 24
News, Press Releases
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
25 Jan 24
Press Releases